Zuzana Baťová, Jana Klimasová
In march 2013, the Committee for Medicinal Product for Human Use (CHMP) at European Medicines Agency adopted a positive opinion, recommending the granting of marketing authorisation for two new medicines – dimethyl fumarate (Aubagio) and teriflunomide (Tecfidera) for the treatment of relaps remitting form of multiple sclerosis. Teriflunomide is selective immunosuppressant with anti-inflammatory properties. Dimethyl fumarate primarily acts by triggering the activation of the Nuclear factor transcriptional pathway. These are the new oral formulations which should increase patients´ compliance.